Andrew H Limper

Title: The Innovations of Andrew H Limper

Introduction

Andrew H Limper is a notable inventor based in Rochester, MN (US). He has made significant contributions to the field of medical research, particularly in understanding and diagnosing infections caused by Pneumocystis carinii. With a total of 2 patents, his work has implications for both therapeutic development and patient care.

Latest Patents

Limper's latest patents include a description of the Cdc2 protein kinase from Pneumocystis carinii. This invention details a nucleic acid and corresponding polypeptide that aids in the regulation of the cell cycle in Pneumocystis carinii. Antibodies generated against a unique carboxyl-terminus region of the polypeptide exhibit specific binding affinity for the P. carinii Cdc2 polypeptide. These antibodies are beneficial in diagnosing and monitoring P. carinii infection in patients. Additionally, the expression of the P. carinii Cdc2 polypeptide in cdc2-mutant yeast and other cdc2-mutant organisms provides a useful model for studying the life cycle of P. carinii and for identifying novel therapeutics.

Career Highlights

Andrew H Limper is affiliated with the Mayo Foundation for Medical Education and Research, where he continues to advance his research. His work has been instrumental in enhancing the understanding of Pneumocystis carinii infections and developing methods for their diagnosis and treatment.

Collaborations

Limper has collaborated with esteemed colleagues such as Edward B Leof and Charles F Thomas, contributing to a rich environment of innovation and research.

Conclusion

Andrew H Limper's contributions to medical research through his patents and collaborations highlight his commitment to improving patient outcomes in the face of Pneumocystis carinii infections. His work continues to pave the way for future innovations in the field.